ImmunoScape, a Singapore-based biotech firm enabling insights into the human immune system, raised USD $11m (SGD $14.8m) in equity financing.
US-based venture firm Anzu Partners led the round, joined by University of Tokyo Edge Capital (UTEC) in Japan, and NPR Holdings in Indonesia.
Led by co-founder and CEO Choon Peng Ng, formerly a senior executive at A*STAR, and co-founder and Chief Operating Officer Dr. Alessandra Nardin, ImmunoScape specializes in deep profiling of immune cells and identification of antigen specific T cells. The company enables pharmaceutical and biotechnologies companies to gain insights from clinical trial patient data and to develop more effective immunotherapies. Its immune profiling platform is already engaged in COVID-19 related programs in global collaborations with Massachusetts General Hospital, University of Parma (Italy), and Duke-NUS. ImmunoScape also has established collaborations with several vaccine development companies, including the San Diego-based Arcturus which is running clinical trials in Singapore.
The technology was based on work begun at Stanford University, and continued at A*STAR of Singapore, where the company was established in 2017.